GRI Bio, Inc. current report, 21 April 2023

Full document

GRI Bio, Inc. Form 8-K Summary

Reporting date: April 21, 2023. The filing was submitted by Vallon Pharmaceuticals, Inc., which changed its name to GRI Bio, Inc. following completion of the merger with GRI Operations, Inc. The transaction is accounted for as a reverse recapitalization, with GRI treated as the accounting acquirer.

Business Context and Transaction

  • Vallon Merger Sub merged with and into GRI, with GRI surviving as a wholly owned subsidiary of the company.
  • Before the merger became effective, the company completed a 1-for-30 reverse stock split.
  • Immediately after closing, approximately 2,957,093 shares of common stock were outstanding. Former GRI stockholders, including the financing investor, owned or held rights to acquire approximately 85% of the company; pre-merger Vallon stockholders held approximately 15%.
  • The stock began trading on Nasdaq under the ticker symbol GRI, on a post-split basis, expected to begin April 24, 2023. The new CUSIP is 3622AW 106.

Financial Metrics, Capitalization and Liquidity

  • The filing does not provide current-period revenue, net income, operating cash flow, cash balances, margins, working capital, or liquidity runway.
  • GRI historically issued bridge senior secured notes with aggregate principal of up to approximately $3.3 million for aggregate proceeds of up to approximately $2.5 million. The filing does not clearly state the outstanding balance at closing or repayment terms.
  • Bridge warrants were exchanged for warrants to purchase 421,589 shares of company common stock at an initial exercise price of $14.73 per share.
  • Under the equity financing, 253,842 shares were issued to the investor and 1,015,368 additional shares were placed in escrow, subject to specified reset dates and beneficial ownership limitations.
  • The company expected to issue additional warrants on May 8, 2023, including Series A-1 warrants for 1,269,210 shares at $13.50 per share, Series A-2 warrants for 1,142,289 shares at $14.73 per share, and Series T warrants relating to 814,467 shares at $12.28 per share, plus additional contingent warrants.

Material Changes Versus the Prior Comparable Period

  • Completed the merger and effected a change in control of the registrant.
  • Changed the corporate name, ticker symbol, CUSIP, board composition, executive leadership, and accounting firm.
  • Replaced EisnerAmper LLP with Sadler, Gibb & Associates LLC as independent registered public accounting firm. The filing reports no prior audit disagreements or reportable events involving EisnerAmper.
  • The historical financial statements of GRI are expected to become the company’s historical financial statements for accounting purposes.
  • The company’s former directors, other than David Baker, resigned. Four directors were appointed, with David Szekeres becoming chairperson.
  • Most former executive officers resigned. W. Marc Hertz became chief executive officer, Leanne Kelly remained or became chief financial officer, Vipin Kumar Chaturvedi became chief scientific officer, and Albert Agro became chief medical officer through a consulting arrangement.

Management, Compensation and Equity Plans

  • Annual base salaries are $375,000 for Dr. Hertz and $312,500 each for Ms. Kelly and Dr. Chaturvedi.
  • Target cash bonuses are 50% for Dr. Hertz, 20% for Ms. Kelly during the first term and 35% thereafter, and 35% for Dr. Chaturvedi.
  • Closing bonuses of $250,000 for Dr. Hertz and $100,000 for Ms. Kelly were paid upon closing.
  • Ms. Kelly is expected to receive an option to purchase 750,000 shares within 180 days after the effective date.
  • Dr. Agro’s consulting fee is $25,000 per month, subject to providing at least 100 hours of services per month.
  • David Baker’s separation arrangement provides for 18 months of salary continuation, a lump-sum payment equal to 150% of his target bonus, certain COBRA benefits, and modifications to specified future milestone payments.
  • Stockholders approved an amended and restated equity incentive plan, increasing shares available for awards by 1,520,151 to 1,950,000, extending the plan through January 1, 2033, and revising director compensation limits and repricing provisions.

Outlook, Risks and Unusual Items

  • The filing does not provide revenue or earnings guidance, clinical development guidance, cash runway estimates, or a specific operating outlook.
  • Key dilution risks include the assumed options and warrants, the investor’s escrowed shares, the planned equity warrants, and additional contingent warrants.
  • The transaction is subject to the risks of a reverse recapitalization, including integration, financing, ownership concentration, and the company’s ability to fund operations.
  • Employment and consulting agreements include severance, COBRA, equity acceleration, and change-in-control provisions that could create material future obligations.
  • The company stated that it would file GRI’s required financial statements and pro forma financial information by amendment to the Form 8-K within 71 calendar days.

Investor Verification Checklist

  • Verify the post-merger share count, fully diluted capitalization, and the percentage ownership and beneficial ownership limitations applicable to the investor.
  • Review GRI’s subsequently filed historical financial statements and pro forma financial information, including cash, liabilities, losses, and going-concern disclosures.
  • Confirm the outstanding bridge debt, security interests, maturity dates, repayment obligations, and any defaults or covenants.
  • Review the full terms and potential dilution from the Exchange Warrants, Equity Warrants, assumed options, and escrowed shares.
  • Assess whether the planned May 8, 2023 warrant issuances occurred and identify any revised terms.
  • Review the new auditor’s report and any subsequent amendments or disclosures concerning internal controls, liquidity, or financing needs.